Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Researchers identify two oncogenes that drive the development of medulloblastoma

A new collaborative study carried out by researchers at Sanford-Burnham Medical Research Institute, UC San Diego, the German Cancer Research Center, the University of Heidelberg (Germany), and 33 other research institutions has identified two oncogenes, called GFI1 and GFI1B, that drive the development of medulloblastoma, the most common malignant brain tumor in children.

23 Jun 2014

Researchers shed new light on how gliomas cells migrate in brain and cause devastating tumors

Researchers at the University of Alabama at Birmingham have shed new light on how cells called gliomas migrate in the brain and cause devastating tumors.

20 Jun 2014

New class of tumor-targeting agents can seek out dozens of solid tumors

Scientists at the University of Wisconsin Carbone Cancer Center (UWCCC) report that a new class of tumor-targeting agents can seek out and find dozens of solid tumors, even illuminating brain cancer stem cells that resist current treatments.

13 Jun 2014

EU-funded project aims to identify potential new targets for cancer therapy

Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.

11 Jun 2014

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Gene variants that lead to longer telomeres boost brain cancer risk

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.

9 Jun 2014

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.

4 Jun 2014

Collaborative research effort produces new genetic insights into brainstem glioma

A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma.

2 Jun 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, a novel paclitaxel-peptide drug conjugate, at the American Society of Clinical Oncology 50th Annual Meeting in Chicago, IL.

31 May 2014

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem announced today that the Food & Drug Association (FDA) has granted both orphan drug and fast track designation to ANG1005 a novel paclitaxel-peptide drug conjugate leveraging the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer, for the treatment of glioblastoma multiforme (GBM).

31 May 2014

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.

31 May 2014

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.

28 May 2014

Study investigates whether use of mobile phones affects children's cognitive development

A new study launching today will investigate whether the use of mobile phones and other wireless technologies might affect children's cognitive development.

21 May 2014

Biochemists identify protein that can slow down growth of brain tumors in mice

Much like using dimmer switches to brighten or darken rooms, biochemists have identified a protein that can be used to slow down or speed up the growth of brain tumors in mice.

12 May 2014

UCSD neurosurgeons study MRI-guided biopsy approach to diagnose patients with brain cancer

Neurosurgeons at UC San Diego Heath System have, for the first time, combined real-time magnetic resonance imaging (MRI) technology with novel non-invasive cellular mapping techniques to develop a new biopsy approach that increases the accuracy of diagnosis for patients with brain cancer.

2 May 2014

Human fat: A Trojan horse to fight brain cancer?

Johns Hopkins researchers say they have successfully used stem cells derived from human body fat to deliver biological treatments directly to the brains of mice with the most common and aggressive form of brain tumor, significantly extending their lives.

1 May 2014

Researchers create tiny, biodegradable nanoparticles that carry DNA to brain cancer cells

Working together, Johns Hopkins biomedical engineers and neurosurgeons report that they have created tiny, biodegradable “nanoparticles” able to carry DNA to brain cancer cells in mice.

30 Apr 2014

Graphene may lead to new applications in the diagnosis and treatment of neurological diseases

The development of graphene-a highly advanced metamaterial with many unique and varied properties-may lead to exciting new applications in the diagnosis and treatment of neurological diseases, according to a report in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

26 Apr 2014

Brain Cancer News and Research

Further Reading

Researchers identify two oncogenes that drive the development of medulloblastoma

Researchers shed new light on how gliomas cells migrate in brain and cause devastating tumors

New class of tumor-targeting agents can seek out dozens of solid tumors

EU-funded project aims to identify potential new targets for cancer therapy

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Celsion signs definitive asset purchase agreement to acquire EGEN

Gene variants that lead to longer telomeres boost brain cancer risk

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Collaborative research effort produces new genetic insights into brainstem glioma

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Study investigates whether use of mobile phones affects children's cognitive development

Biochemists identify protein that can slow down growth of brain tumors in mice

UCSD neurosurgeons study MRI-guided biopsy approach to diagnose patients with brain cancer

Human fat: A Trojan horse to fight brain cancer?

Researchers create tiny, biodegradable nanoparticles that carry DNA to brain cancer cells

Graphene may lead to new applications in the diagnosis and treatment of neurological diseases

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News